Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 36Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Colorectal Neoplasms 6Carcinoma, Renal Cell 5Breast Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Lymphoma, Follicular 4Uveal Melanoma 3Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Merkel Cell 3Thyroid Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2

Interventions

pembrolizumab 1Taxes 1Pemetrexed 1Paclitaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Cisplatin × Dermatologic × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡